Valeo Financial Advisors, LLC Viracta Therapeutics, Inc. Transaction History
Valeo Financial Advisors, LLC
- $4.33 Billion
- Q1 2025
Shares
2 transactions
Others Institutions Holding VIRX
# of Institutions
13Shares Held
467KCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY273KShares$5,4650.0% of portfolio
-
Xtx Topco LTD London, X093.4KShares$1,8670.0% of portfolio
-
United Capital Financial Advisers, LLC Newport Beach, CA43KShares$8590.0% of portfolio
-
Wealth Trust Axiom LLC16.4KShares$3270.0% of portfolio
-
Baader Bank Aktiengesellschaft Unterschleissheim, 2M15.3KShares$3050.0% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $751K
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...